NCT02985619View on ClinicalTrials.gov

Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 21, 2016

Primary Completion Date

April 14, 2017

Study Completion Date

December 21, 2017

Conditions
Diabetic Macular Edema
Interventions
DRUG

Bevacizumab Injection [Avastin] (IVB-I)

0,05ml intravitreal injection

DRUG

Triamcinolone Acetonide 10mg/mL (IVT-II)

0,03ml intravitreal injection

DRUG

Bevacizumab Injection [Avastin] (IVB-III)

0,05ml intravitreal injection

All Listed Sponsors
lead

University of Sao Paulo

OTHER

NCT02985619 - Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema | Biotech Hunter | Biotech Hunter